Antibe Therapeutics Announces Appointments of New President/CEO and CFO
CALGARY , ALBERTA , August 17, 2005 — Antibe
Therapeutics Inc., an early-stage drug development company, is pleased to
announce the appointments of Daniel Legault as President and Chief Executive
Officer and Alain Wilson as Chief Financial Officer of the Company.
Daniel Legault brings extensive strategic management experience
to Antibe, having led a number of fast growing companies. He is a founding
principal of Revelstoke Partners, a Toronto-based merchant bank focused on
assisting companies in challenging situations, ranging from sophisticated,
later-stage startups approaching commercialization to more mature but
under-performing companies. Prior to founding Revelstoke Partners, Dan was
President of Opal Sky, the pioneering CRM strategy and technology services
company, and the President of Butterfield & Robinson, the renowned high-end
tour operator. Dan is on the Board of Directors of Green Shield Canada , one of
the country's largest health and drug benefits insurers, and Save the Children.
Dan obtained his law degree at Queen's University, and is a Member of the Law
Society of Upper Canada and the New York Bar.
Alain Wilson brings to Antibe extensive experience in
international strategic and financial management across a number of different
industries. He is also a founding partner of Revelstoke Partners prior to which
he had an extensive career in management consulting. Alain was the Office Head
of Mercer Management Consulting in Toronto . Alain also brings experience in
the software and services business, co-founding and serving as Chief Operating
Officer for a leading CRM solutions provider. Alain obtained a B. Comm. at
Queen's University and an MBA at IMD in Switzerland .
Antibe’s founding President and CEO, Dr. John Wallace ,
remarked: “Dan Legault and Alain Wilson bring tremendous management and
leadership skills to Antibe Therapeutics and will be instrumental in
facilitating the further development of our lead compounds and in achieving a
favourable exit for our investors. We are also pleased to establish a new
office in the heart of Canada 's primary financial district”. Dr. Wallace will
undertake the role of Chief Scientific Officer and will remain as Chairman of
the Board of Directors.
About Antibe Therapeutics, Inc.
Antibe (pronounced ‘on-teeb ’) Therapeutics (www.antibe-therapeutics.com) is a privately-held early-stage drug development company
headquartered in Calgary , Canada with affiliate laboratories in the
USA , United Kingdom , Italy and Brazil . The Company's pipeline
consists of drugs targeting serious chronic diseases, including
inflammatory bowel disease, erectile dysfunction, irritable bowel
syndrome, pulmonary hypertension and various complications of diabetes.
Antibe's drug development platform
involves the assimilation of small vasoactive/immunomodulatory
components to existing drugs to generate new chemical entities that are
significantly improved over the parent molecules and/or serve unmet
medical needs.
With more than 50 years combined experience in the pharmaceutical and
biotech sectors, Antibe's senior management team has a well-defined
track record in the development of anti-inflammatory and vasoactive
drugs, for which they have received approval from various regulatory
boards inclusive of the US FDA.
For further information regarding ATB-901 and other drug development programs,
please contact:
Dr. John Wallace
Antibe Therapeutics, Inc
(403) 220-4539